DOR-NOTICE OF FILING
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
 
Washington, D.C. 20549
 
FORM 12b-25
 
 
SEC File No.
 
 
000-16929
 
 
NOTIFICATION OF LATE FILING
 
 
(Check One): [ X ] Form 10-K  [  ] Form 20-F  [  ] Form 11-K  [ ] Form 10-Q  [  ] Form N-SAR
 
 
For Period Ended:  December 31, 2005
 
 
[  ] Transition Report on Form 10-K
 
 
[  ] Transition Report on Form 20-F
 
 
[  ] Transition Report on Form 11-K
 
 
[  ] Transition Report on Form 10-Q
 
 
[  ] Transition Report on Form N-SAR
 
 
For the Transition Period Ended: ___________________
 
 
 
Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
 
 
If the notification relates to a portion of the filing checked above, identify the item(s) to which the notification relates:
 
 
The entire Form 10-KSB for the period ended December 31, 2005
 
PART I -- REGISTRANT INFORMATION
 
Dor BioPharma, Inc. ___________________________________________________________________________________
Full Name of Registrant                        
___________________________________________________________________________________________________________________________ Former Name if Applicable
Lincoln Building, 1691 Michigan Avenue, Suite 435________________________________________________________________
Address of Principal Executive Office (Street and Number) 
         
City, State and Zip Code: Miami, Florida 33139
 
PART II -- RULES 12b-25(b) AND (c)
 
 
If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed.
 
 
[X] (a) The reasons described in reasonable detail in Part III of this form could not be eliminated without
unreasonable effort or expense.
[X] (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K or
Form N-SAR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed
due date; or the subject quarterly report of transition report on Form 10-Q, or portion thereof will be filed on
or before the fifth calendar day following the prescribed due date
[ ] (c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
   
 

 
 
PART III -- NARRATIVE
 
State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, N-SAR, or the transition report portion thereof, could not be filed within the prescribed time period.

The Company was unable to file its Form 10-KSB for the year ended December 31, 2005 within the prescribed time period without unreasonable effort and expense. The Company started to transmit the document to the Commission prior to 5:30 p.m. on March 31, 2006 but, due to the number of registrants attempting to make filings with the Commission on that date, the document was not received by the Commission by the filing deadline. The Company filed its Form 10-KSB on April 3, 2006.
 
PART IV-- OTHER INFORMATION
 
 
(1) Name and telephone number of person to contact in regard to this notification
 
Michael T. Sember
(Name)
305
(Area Code)
534 3383
(Telephone Number)
 
(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). [X] Yes [ ] No _____________________________________________________________________________________________
 
 
(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? [ ]Yes [X] No
 
 
Dor BioPharma, Inc.
 
 
(Name of Registrant as Specified in Charter)
 
 
has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.
 
Date:  April 3, 2006        By: /s/ Michael T. Sember___________________
Michael T. Sember, Chief Executive Officer